Teligent, Inc. , announced that it has received approvals of the Company's abbreviated new drug applications (ANDAs) from the U.S. Food and Drug Administration (FDA) for both Triamcinolone Acetonide Lotion USP, 0.1% and Triamcinolone Acetonide Lotion USP, 0.025%. The FDA has now approved seven ANDAs from the Company's internally developed pipeline of topical generic pharmaceutical products.
[adsense:336x280:8701650588]
Based on IMS Health data from May 2016, the total addressable market for these two products is approximately $6.8 million.
[adsense:468x15:2204050025]
"We are excited to add these two new products to our growing portfolio of topical prescription medicines," commented Jason Grenfell-Gardner, President and CEO of the Company. "We have now received six approvals from the FDA this year, including an earlier approval of a partnered submission. Our team is committed to bringing these products to market this quarter.''
